(Reuters)—Eli Lilly and Co. on Wednesday embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen, saying it could lower the cost of insulin and other prescription drugs for patients. Lilly, along with other major insulin makers, Sanofi SA and Novo Nordisk, has been under mounting pressure from…
B Cell-Directed Therapy May Delay RA Development in High-Risk Patients
New evidence from a clinical trial of rituximab has identified the pathogenetic role of B cells in the earliest, pre-arthritis stage of autoantibody-positive RA…
U.S. Government Proposes Rule Overhauling Drug Industry Rebate System
NEW YORK (Reuters)—The U.S. government proposed a rule to end the industry-wide system of after-market discounts called rebates that pharmacy benefit managers receive from drugmakers, a practice that has been under scrutiny. If finalized, the rule would change a system that has been in place for decades and that increasingly has been criticized for obfuscating…
U.S. Judge Throws Out Maryland Bid to Protect Obamacare
WASHINGTON (Reuters)—On Feb. 1, a U.S. judge threw out the state of Maryland’s bid to protect the healthcare law, known as Obamacare, in a ruling that also sidestepped a decision on whether President Donald Trump’s appointment of Matthew Whitaker as acting attorney general was lawful. In a win for the Republican president, Baltimore-based U.S. District…
U.S. Senate Finance Committee Invites Pharma Execs to Testify
WASHINGTON (Reuters)—A powerful U.S. Senate committee on has invited seven pharmaceutical companies to testify at a hearing later this month examining rising prescription drug prices. Sen. Chuck Grassley (R-IA), chairman of the Senate Finance Committee, and Sen. Ron Wyden (D-Ore.), ranking member of the committee, invited executives from AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Co.,…
RA Effectiveness Differs Among Non-TNF Inhibitors
NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…
Walking Ability of OA Patients Linked to Cardiovascular Risk
New research explores the association of the ability to walk and the risk of cardiovascular disease in OA patients compared with the general population. During the study, researchers recorded a six-minute walking distance and measured arterial stiffness of participants. The results: Even among younger people, OA patients could not walk as far as those in the general population. Also, arterial stiffness was inversely associated with walking distance, suggesting walking is important to the cardiovascular risk profile of OA patients…
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone
Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…
Early Onset of Primary Sjögren’s Syndrome May Carry a Worse Prognosis
Research has found age at disease onset has an impact on prognosis for patients with primary Sjögren’s syndrome. In the study, early onset primary Sjögren’s syndrome was associated with severe, systemic disease and development of lymphoproliferative disease…
U.S. Lawmaker Yarmuth Says Democrats to Begin Medicare for All Hearings
WASHINGTON (Reuters)—Democrats in control of the U.S. House of Representatives will begin holding hearings on expanding Medicare this spring and will aim to pass a bill by the end of next year, a senior Democratic lawmaker said on Tuesday. John Yarmuth, chairman of the House Budget Committee, said in an interview with Reuters that the…
- « Previous Page
- 1
- …
- 283
- 284
- 285
- 286
- 287
- …
- 814
- Next Page »